cjc-1295 ipamorelin clinical trial safety adverse events Photos by Prof. Patrick J. Treacy (@ptreacy) · April 17, 2026 CJC-1295 / Ipamorelin Peptide Therapy:

McKenzie T, Liu Y, Swisher S , Pataer A, Chada S, Fanale M, Hunt K

Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population

Highly endemic areas and adult males should be prioritized for chemotherapy (285)

Ercan H, Birben E, Dizdar EA, Keskin O, Karaaslan C, et al: Oxidative stress and genetic and epidemiologic determinants of oxidant injury in childhood asthma